Shanghai Henlius Biotech, Inc.

2696

CNE100003N76

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 09:08:42 28/06/2024 BST			5-day change	1st Jan Change
22.85 ^HKD	-0.65%		+21.28%	+64.39%

06-28	Shanghai Henlius Biotech, Inc. Announces Completion of Phase 1 Clinical Study of a Biosimilar of Daratumumab HLX15 (Recombinant Anti-CD38 Human Monoclonal Antibody	CI
06-25	Hong Kong Stocks Rebound After 3 Days in Red on Rate Cut Hopes; Henlius Soars 19% on Merger Offer	MT

Shanghai Fosun Pharmaceutical Co., Ltd. agreed to acquire 40.44% stake in Shanghai Henlius Biotech, Inc..

June 23, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) agreed to acquire 40.44% stake in Shanghai Henlius Biotech, Inc. (SEHK:2696) on June 24, 2024. The Board of Directors of Shanghai Henlius Biotech, Inc. formed a special committee for the transaction.

China International Capital Corporation Limited acted as financial advisor for Shanghai Fosun Pharmaceutical Co., Ltd. Rainbow Capital Limited acted as financial advisor for Shanghai Fosun Pharmaceutical Co., Ltd.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	SHANGHAI HENLIUS BIOTECH, INC.	22.85 HKD	-0.65%	+21.28%	1.59B
	SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.	22.14 CNY	-0.05%	-1.38%	7.39B

Latest news about Shanghai Henlius Biotech, Inc.

Shanghai Henlius Biotech, Inc. Announces Completion of Phase 1 Clinical Study of a Biosimilar of Daratumumab HLX15 (Recombinant Anti-CD38 Human Monoclonal Antibody	06-28	CI
Hong Kong Stocks Rebound After 3 Days in Red on Rate Cut Hopes; Henlius Soars 19% on Merger Offer	06-25	MT
Henlius Biotech Shares Surge After Fosun's Buyout Offer	06-25	DJ
Fosun Pharma Signs HK$13.4 Billion Merger Offer for Henlius Biotech; Henlius Shares Soar 19%	06-25	MT
Shanghai Fosun Pharmaceutical Co., Ltd. agreed to acquire 40.44% stake in Shanghai Henlius Biotech, Inc..	06-23	CI
Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation	05-24	MT
Henlius' EU Marketing Application for Denosumab Biosimilar Accepted and Validated by Regulator	05-24	MT
Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications for Hlx14	05-24	CI
Shanghai Henlius Biotech, Inc. Announces Marketing Authorization Applications for Biosimilar of Denosumab HLX14 (Recombinant Anti-Rankl Human Monoclonal Antibody Injection) Validated by the European Medicines Agency	05-24	CI
Henlius Biotech Gets China Approval for New Indications of Arthritis Drug	05-22	MT
Henlius Biotech Amends License Deals with Palleon for Bifunctional Protein Products	05-22	MT
National Medical Products Administration Approves Shanghai Henlius Biotech, Inc.'S the Supplemental Applications of Handayuan (Adalimumab Injection) for the New Indications	05-22	CI
US FDA Grants Investigational New Drug Clearance for Alligator Bioscience's Late-stage Gastric Cancer Treatment Trial	05-21	MT
Shanghai Henlius Biotech, Inc. Announces Amendments to the Collaboration and License Agreement with Palleon for Tumour-Related Target-Sialidase Bifunctional Fusion Protein	05-21	CI
Shanghai Henlius Biotech, Inc. Receives Investigational New Drug Clearance from the US Food and Drug Administration to Initiate Hlx22 in 1st Line HER2+ Gastric Cancer Patients	05-21	CI
Shanghai Henlius Biotech Gets Go-Ahead for Clinical Trials of Breast Cancer Drug in China	05-14	MT
Shanghai Henlius Biotech, Inc. Announces Approval of Application for Clinical Trials of HLX78 (lasofoxifene) by the National Medical Products Administration	05-14	CI
Henlius Biotech Gets US FDA Clearance for Phase 3 Trial of Gastric Cancer Combination Therapy	05-06	MT
Shanghai Henlius Biotech, Inc. Announces Application for the Phase 3 Clinical Trial of HLX22 in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment of HER2 Positive Advanced Gastric Cancer Approved by the United States Food and Drug Administration	05-06	CI
Henlius Biotech Logs 1.35 Billion Yuan Revenue in Q1	05-01	MT
Shanghai Henlius Biotech's Cancer Drug Gets the Nod from US FDA	04-26	MT
Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China	04-24	MT
Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China	04-23	CI
Henlius Biotech Gets Clearance for China Clinical Trial of Carcinoma Drug	04-17	MT
Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of HLX53 (Anti-TIGIT Fc Fusion Protein) in Combination with HANSIZHUANG (Serplulimab Injection) and HANBEITAI (Bevacizumab Injection) for the First-Line Treatment of Local Advanced or Metastatic Hepatocellular Carcinoma was Approved by the National Medical Products Administration	04-17	CI

Chart Shanghai Henlius Biotech, Inc.

Duration

Period

More charts

Company Profile

Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Companyâs main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.

Sector

Pharmaceuticals

Calendar

14/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Shanghai Henlius Biotech, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

21.27 CNY

Average target price

18.79 CNY

Spread / Average Target

-11.64%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
SHANGHAI HENLIUS BIOTECH, INC.	+64.39%	1.59B
CSL LIMITED	+2.99%	95.18B
SAMSUNG BIOLOGICS CO.,LTD.	-4.34%	37.55B
BIOGEN INC.	-10.41%	33.75B
UCB	+75.79%	28.2B
BIOMARIN PHARMACEUTICAL INC.	-14.61%	15.63B
INCYTE CORPORATION	-3.46%	13.63B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.31%	11.5B
ALTEOGEN INC.	+184.77%	10.81B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-54.13%	9.23B

Biopharmaceuticals

Shanghai Henlius Biotech, Inc.

Equities

2696

CNE100003N76

Pharmaceuticals

Shanghai Fosun Pharmaceutical Co., Ltd. agreed to acquire 40.44% stake in Shanghai Henlius Biotech, Inc..

Stocks mentioned in the article

Latest news about Shanghai Henlius Biotech, Inc.

Chart Shanghai Henlius Biotech, Inc.

Company Profile

Income Statement Evolution

Ratings for Shanghai Henlius Biotech, Inc.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Biopharmaceuticals